- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04633382
ENHANCED RECOVERY AFTER BILIARY TRACT SURGERY
November 17, 2020 updated by: Yury Arlouski, Vitebsk State Medical University
JUSTIFICATION OF THE PRINCIPLES OF ENHANCED RECOVERY AFTER BILIARY TRACT SURGERY
The aim of the study is to improve the immediate results after reconstructive and restorative operations on the biliary tract by substantiating the management of the perioperative period on the principles of "enhanced recovery after surgery".
Study Overview
Status
Unknown
Intervention / Treatment
Detailed Description
A prospective randomized study on the effect of fast-track surgery on the immediate postoperative results after various reconstructive and restorative operations on the bile ducts.
In the Department of Surgical Hepatology and Transplantation, a prospective randomized study will include patients (about 50) with planned reconstructive and restorative operations on the bile ducts for malignant and benign diseases of the bile ducts.
Study Type
Interventional
Enrollment (Anticipated)
50
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
Patients with malignant diseases of the biliary tract (cholangiocarcinoma):
1.1. tumor resectability 1.2. absence:
- distant metastases
- carcinomatosis
- perforation of the tumor and peritonitis
- sprouting into adjacent organs and tissues (locally advanced cancer)
- total adhesion process in the abdominal cavity (after previous operations). 1.3. Planned reconstructive surgery on the biliary tract.
Patients with benign biliary tract pathology. 2.1. Planned reconstructive or restorative surgery on the biliary tract for the following diseases:
- choledocholithiasis
- Mirizzi syndrome
- cysts of the common bile duct
- strictures of the common bile duct
- injuries to the bile ducts
- adenoma and stricture of the OBD
Exclusion Criteria:
- Scale ASA> III (severe concomitant cardiovascular pathology).
- Palliative reconstructive surgery.
- Previously performed operations on the bile ducts (up to 1 month).
- Cachexia.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Conducting research of enhanced recovery after surgery
|
Patients with malignant and benign diseases of the bile ducts, who have formed various types of anastomosis in two options for managing the postoperative period: traditional and based on the principles of enhanced recovery after surgery
|
|
Placebo Comparator: Conducting research of traditional recovery after surgery
|
Patients with malignant and benign diseases of the bile ducts, who have formed various types of anastomosis in two options for managing the postoperative period: traditional and based on the principles of enhanced recovery after surgery
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Reduction of bed-days
Time Frame: 1 week
|
Improvement of basic health indicators, absence of complications, reduction of bed days
|
1 week
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Anticipated)
January 1, 2021
Primary Completion (Anticipated)
January 31, 2021
Study Completion (Anticipated)
January 1, 2022
Study Registration Dates
First Submitted
November 12, 2020
First Submitted That Met QC Criteria
November 12, 2020
First Posted (Actual)
November 18, 2020
Study Record Updates
Last Update Posted (Actual)
November 19, 2020
Last Update Submitted That Met QC Criteria
November 17, 2020
Last Verified
November 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Biliary interventional
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cholangiocarcinoma
-
Mayo ClinicTerminatedStage III Intrahepatic Cholangiocarcinoma AJCC v8 | Metastatic Cholangiocarcinoma | Refractory Cholangiocarcinoma | Stage III Hilar Cholangiocarcinoma AJCC v8 | Stage IV Hilar Cholangiocarcinoma AJCC v8 | Stage IV Intrahepatic Cholangiocarcinoma AJCC v8 | Advanced CholangiocarcinomaUnited States
-
University of Kansas Medical CenterNational Cancer Institute (NCI)Active, not recruitingStage III Intrahepatic Cholangiocarcinoma AJCC v8 | Metastatic Cholangiocarcinoma | Locally Advanced Cholangiocarcinoma | Stage III Hilar Cholangiocarcinoma AJCC v8 | Stage IV Hilar Cholangiocarcinoma AJCC v8 | Stage IV Intrahepatic Cholangiocarcinoma AJCC v8 | Recurrent CholangiocarcinomaUnited States
-
M.D. Anderson Cancer CenterActive, not recruitingStage III Intrahepatic Cholangiocarcinoma AJCC v8 | Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8 | Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8 | Stage IV Intrahepatic Cholangiocarcinoma AJCC v8 | Metastatic Intrahepatic Cholangiocarcinoma | Locally Advanced Intrahepatic CholangiocarcinomaUnited States
-
Mayo ClinicNational Cancer Institute (NCI)RecruitingStage III Intrahepatic Cholangiocarcinoma AJCC v8 | Stage IV Intrahepatic Cholangiocarcinoma AJCC v8 | Unresectable Intrahepatic Cholangiocarcinoma | Locally Advanced Intrahepatic Cholangiocarcinoma | Oligometastatic Intrahepatic CholangiocarcinomaUnited States
-
National Cancer Institute (NCI)CompletedStage III Intrahepatic Cholangiocarcinoma AJCC v8 | Gallbladder Carcinoma | Metastatic Cholangiocarcinoma | Stage IV Intrahepatic Cholangiocarcinoma AJCC v8 | Unresectable CholangiocarcinomaUnited States
-
RedHill Biopharma LimitedCompletedCholangiocarcinoma | Cholangiocarcinoma Non-resectable | Cholangiocarcinoma, Perihilar | Cholangiocarcinoma, Extrahepatic | Cholangiocarcinoma, IntrahepaticUnited States
-
RedHill Biopharma LimitedNo longer availableCholangiocarcinoma | Cholangiocarcinoma Non-resectable | Cholangiocarcinoma, Perihilar | Cholangiocarcinoma, Extrahepatic | Cholangiocarcinoma, Intrahepatic
-
Emory UniversityNational Cancer Institute (NCI); National Institutes of Health (NIH); CelgeneCompletedResectable Cholangiocarcinoma | Stage IB Intrahepatic Cholangiocarcinoma AJCC v8 | Stage II Intrahepatic Cholangiocarcinoma AJCC v8 | Stage III Intrahepatic Cholangiocarcinoma AJCC v8 | Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8 | Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8United States
-
Emory UniversityNational Cancer Institute (NCI)WithdrawnStage II Intrahepatic Cholangiocarcinoma AJCC v8 | Stage III Intrahepatic Cholangiocarcinoma AJCC v8 | Resectable Intrahepatic Cholangiocarcinoma | Stage 0 Intrahepatic Cholangiocarcinoma AJCC v8 | Stage I Intrahepatic Cholangiocarcinoma AJCC v8United States
-
AIO-Studien-gGmbHServierCompletedCholangiocarcinoma Non-resectable | Cholangiocarcinoma of the Gallbladder | Cholangiocarcinoma Metastatic | Cholangiocarcinoma AdvancedGermany
Clinical Trials on Enhanced recovery after biliary tract surgery
-
Instituto Brasileiro de Controle do CancerWithdrawnEnhanced Recovery After Surgery | Gynecologic Surgical ProceduresBrazil
-
National Taiwan University HospitalEnrolling by invitationPediatric | Lung Surgery | Enhanced Recovery After Surgery, ERASTaiwan
-
The Second Hospital of Shandong UniversityRecruitingLung Cancer | Surgery | ERASChina
-
Instituto Brasileiro de Controle do CancerRecruitingGynecologic Cancer | Enhanced Recovery After SurgeryBrazil
-
Sixth Affiliated Hospital of Xinjiang Medical UniversityNot yet recruiting
-
University of ThessalyRecruitingPancreatic Cancer Resectable | Enhanced Recovery After Surgery | PancreatectomyGreece
-
Chonnam National University HospitalCompleted
-
The Second Hospital of Shandong UniversityNot yet recruiting
-
Services Hospital, LahoreCompletedEnhanced Recovery After SurgeryPakistan
-
University of Colorado, DenverRecruitingEnhanced Recovery After Surgery | Gynecologic DiseaseUnited States